Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease

Eur J Neurol. 2006 Nov;13(11):1186-202. doi: 10.1111/j.1468-1331.2006.01548.x.

Abstract

To provide evidence-based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non-motor complications, either disease-related (e.g. freezing) or treatment-related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non-European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement ('good practice point') is made.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiparkinson Agents / therapeutic use
  • Autonomic Nervous System Diseases / drug therapy*
  • Autonomic Nervous System Diseases / etiology
  • Deep Brain Stimulation
  • Humans
  • Mental Disorders / drug therapy
  • Mental Disorders / etiology
  • Mental Disorders / therapy*
  • Movement Disorders / drug therapy
  • Movement Disorders / etiology
  • Movement Disorders / physiopathology
  • Movement Disorders / therapy*
  • Neurosurgical Procedures
  • Parkinson Disease / complications*
  • Parkinson Disease / psychology*

Substances

  • Antiparkinson Agents